所属 医学部 医学科（東京女子医科大学病院） 職種 教授
|表題||Effectiveness and safety of dabigatran versus warfarin in real-world Japanese patients with atrial fibrillation: A single-center observational study|
|掲載誌名||正式名：Journal of Arrhythmia|
略 称：J Arrhythmia
|出版社||Japanese Heart Rhythm Society|
|著者・共著者||NAGANUMA Miyoko†, SHIGA Tsuyoshi*, NAGAO Takehiko, SUZUKI Atsushi, MURASAKI Kagari, HAGIWARA Nobuhisa|
In "real-world" practice, anticoagulant therapy is indicated for patients whose clinical profiles are not addressed in randomized clinical trials. We assessed the effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with non-valvular atrial fibrillation (NVAF).
Among 613 NVAF patients who initiated dabigatran or warfarin therapy during the period between 2011 and 2013, 362 patients were included in the study after propensity score adjustment. The median follow-up period was 1.3 years. The effectiveness and safety outcomes were thromboembolism and major bleeding, respectively.
The propensity-matched hazard ratios of thromboembolism and major bleeding with dabigatran were 1.03 (95% CI: 0.12-8.04, p=0.971) and 0.15 (95% CI: 0.01-0.90, p=0.037), respectively.
The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in "real-world" NVAF patients.